Small Molecules of the Month – Oct. 2021

The October edition of Small Molecules of the Month includes several potential best-in-class clinical candidates including but not limited to a second-gen LPA1 antagonist from BMS, two muscle modulators from Cytokinetics, and a Janssen pan-genotype, pan-serotype Dengue virus inhibitor. There …

CD47-SIRPα Drug Target Minireview

In Aug. 2021, immuno-oncology company, Trillium Therapeutics, was acquired by Pfizer for $2.3 billion, adding Trillium’s two CD47-targeting biologics, TTI-621 and TTI-622, to Pfizer’s oncology pipeline. The acquisition followed Gilead’s $4.9B buyout of Forty Seven in early 2020, after clinical …

Small Molecules of the Month – Sep. 2021

The September edition of Small Molecules of the Month, features a number of fascinating molecules and mechanisms, including a beta-lactamase inhibitor optimized to have single agent antibiotic activity, a biased agonist of S1P1 that minimizes receptor internalization in favor of …

6. BMS-986318 – BMS cyclobutene-containing FXR agonist

Small Molecules of the Month – Aug. 2021

The August edition of Small Molecules of the Month, features a recently approved, dibasic oral kallikrein inhibitor, a spirocyclobutene-containing FXR agonist, a NaV1.6 clinical candidate, a remarkably long acting RIPK2 PROTAC, and several other interesting clinical candidates. Thanks to reviewers …